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Abstract
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is 
a hereditary endocrine tumor syndrome characterized by 
the triad of primary hyperparathyroidism, duodenopancre-
atic neuroendocrine tumors (pNETs), and pituitary tumors. 
Patients are confronted with substantial morbidity and are 
consequently at risk for an impaired quality of life (QOL). Me-
ticulous assessment of QOL and associated factors in a rep-
resentative population is needed to understand the full 
spectrum of the burden of the disease. Patients and Meth-
ods: A cross-sectional study was performed using the na-
tional Dutch MEN1 cohort. Patients with a confirmed MEN1 
mutation received the SF-36 Health Related Quality of Life 
questionnaire and questions regarding sociodemographic 
and medical history. Results: A total of 227 of 285 (80%) eli-
gible MEN1 patients returned the questionnaires. Health-re-
lated QOL scores (HRQOL) in MEN1 patients were significant-
ly lower for the majority of subscales of the SF-36 in com-
parison with the general Dutch population. The most 
consistent predictor for HRQOL was employment status, fol-
lowed by the presence of a pituitary tumor. 16% of patients 
harboring a pNET and 29% of patients with a pituitary tumor 
according to the medical records, reported that they were 
unaware of such a tumor. These subgroups of patients had 
several significant better QOL scores than patients who were 
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aware of their pNET or pituitary tumors. Conclusion: Patients 
with MEN1 have an impaired QOL in comparison with the 
general Dutch population warranting special attention with-
in routine care. For daily practice, physicians should be aware 
of their patients’ impaired QOL and of the impact of unem-
ployment on QOL. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Multiple endocrine neoplasia type 1 (MEN1) is a he-
reditary disease characterized by the classic triad of pri-
mary hyperparathyroidism (pHPT), pancreatic neuroen-
docrine tumors (pNETs), and pituitary tumors [1, 2]. 
Other encountered neoplasms are neuroendocrine tu-
mors of thymic, bronchial, or gastric origin, adrenal tu-
mors, and smooth muscle, skin, and subcutaneous tu-
mors [3]. Recently, it was reported that females with 
MEN1 have an almost 3 times higher risk for breast can-
cer at a 15 years younger age, which underlines the com-
plexity and severity of the disease [4, 5].
The penetrance of the disease is high, especially for 
pHPT, pNETs, and pituitary tumors, respectively 100, 80, 
and 70%, with the first manifestations occurring in child-
hood, further contributing to the burden of the disease for 
MEN1 mutation carriers [6, 7]. Confronted by this knowl-
edge, accompanied by significant morbidity and early 
mortality, nowadays mostly arising from pNETs, MEN1 
patients are at risk for impaired quality of life (QOL) [8, 9].
Recently it was reported that MEN1 patients have a 
high fear of MEN1-related tumor recurrence [8]. Studies 
assessing the health-related QOL (HRQOL) of patients 
with MEN1 indicate an impaired HRQOL, with a higher 
rate of depression for patients with a high burden of dis-
ease and treatment [9]. It is also suggested that HRQOL 
in MEN1 patients is worse than HRQOL in the general 
population [9, 10]. Unfortunately, due to the manner of 
recruiting the participants, the studied populations were 
often prone for selection bias. Since these studies recruit-
ed in hospital patients or via patients’ support groups, 
supposedly patients in need of medical or peer support 
were included. Therefore, the reported HRQOL might 
not be generalizable to the total MEN1 patient popula-
tion. In addition, in several reports, medical information 
was assessed by self-reporting and there was no access to 
the medical records to retrieve the actual medical disease 
status. Therefore, it was unclear whether the reported dis-
ease status of patients was accurate [9, 11]. In this respect, 
it is also not known whether these patients were actual 
genetically proven MEN1 patients or so-called “pheno-
copies,” who have been reported to be a different disease 
entity with a more indolent disease course [6].
The Dutch MEN1 Study Group (DMSG) has meticu-
lously registered the Dutch MEN1 population in a na-
tional database. This database contains data from 1990 up 
to present, collected every quarter of every year. The de-
sign of long follow-up and high density of the data allows 
for an accurate representation of disease status of all pa-
tients. This high coverage also minimizes the occurrence 
of a selected study sample [12].
The primary aim of this study was to assess HRQOL in 
the Dutch MEN1 cohort in order to compare the HRQOL 
with the general Dutch population and to assess which 
variables were predicators for worse HRQOL. The sec-
ondary aim was to evaluate if the self-reported MEN1 
manifestations were in line with the disease status as re-




Participants were recruited from the Dutch MEN1 cohort. This 
MEN1 cohort is established by the DMSG. Participants were re-
trieved from the DMSG database. This longitudinal database in-
cludes > 90% of all Dutch MEN1 patients, aged 16 years and older 
at the end of 2017, treated at one of the Dutch University Medical 
Centers (UMCs) between 1990 up to present [12]. Patients were 
eligible for the present study if they had a confirmed MEN1 muta-
tion. Demographic and clinical data such as MEN1-related medi-
cal history were retrieved from this database.
Disease Manifestations
pHPT was defined as hypercalcemia combined with elevated or 
inappropriately non-suppressed parathyroid hormone levels in 2 
consecutive measurements. The presence of a pNET was con-
firmed according to the outcome of pathology examination. If 
pathological diagnosis was not available, pNET presence was based 
on MRI, computed tomography, or endoscopic ultrasound, which 
had to be confirmed at least once by consecutive imaging studies. 
Pathological diagnosis was generally not available in patients that 
were not eligible for surgery, for example, in case of a small tumor 
size. The absence of a pNET also had to be confirmed on a mini-
mum of 2 subsequent imaging studies during follow-up. The refer-
ence standard for the presence of pituitary tumors was (1) pathol-
ogy or (2) consecutive radiological examination demonstrating a 
pituitary tumor. Details for the reference standard of pHPT, pNET, 
and pituitary tumors have been described previously [13–15].
Study Design
A cross sectional study was conducted in which eligible patients 
were invited to complete a questionnaire from April 2015 till De-
cember 2017. After 2 weeks, a reminder e-mail was sent to the par-
ticipants. The questionnaire could be completed by hand or as a 
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web-based questionnaire. All participants provided written in-
formed consent. Data from this cohort has been published earlier 
[8]. The Medical Ethical Committees (MERC) of all UMCs in the 
Netherlands confirmed that the Medical Research Involving Hu-
man Subjects Act (WMO) did not apply for this study and there-
fore, an official approval was not required under WMO.
Questionnaires
Sociodemographic data such as education and employment 
were obtained.
Disease Status. Participants had to complete questions on the 
presence of their own history of pHPT, pituitary tumors, and 
pNETs. In addition they were asked if they were operated or re-
ceived other treatments for these manifestations. If they were oper-
ated the exact year of surgery was asked.
Health-Related Quality of Life. HRQOL was assessed using 
the Short Form 36 (SF-36) Health Survey composed of 8 multi-
item scales assessing physical functioning, role limitations due 
to physical health problems and emotional problems, bodily 
pain, general health perceptions, vitality, social functioning, and 
general mental health. Scale scores range from 0 to 100, with 
higher scores indicating better levels of functioning and well-
being. Cronbach’s α for the SF-36 scales ranged from 0.84 (social 
functioning) to 0.93 (physical pain). Only general health percep-
tion had a low Cronbach’s α (0.55), which will therefore be of 
low significance.
The normative data on the SF-36 Health Survey were derived 
from the general population of the Netherlands [16].
Statistical Analysis
Descriptive statistics were applied to characterize the study 
population. Univariate analyses (independent sample t test/Mann-
Whitney U test, chi-square test/Fisher’s exact test, Pearson correla-
tion) were used when appropriate and to evaluate which MEN1-
related manifestations and sociodemographic variables were as-
sociated with HRQOL.
A multivariable analysis adjusted for age and gender was car-
ried out using multiple linear regression to assess which patient 
characteristics were associated with HRQOL. Collinearity was 
tested using variance inflation factors (VIF). In the linear models, 
none of the VIF values were > 1.6, suggesting that collinearity was 
not a problem.
Analyses were conducted using SPSS 22.0. p values < 0.05 were 
considered as statistically significant.
Results
Response Rate
Between 2015 and 2017, a total of 285 patients (120 
men and 165 women) were eligible for inclusion, of which 
252 (102 men and 150 women) received the question-
naire. Thirty-three patients could not be reached. The 
questionnaire was completed by 227 individuals (84 
[70%] men and 143 [87%] women), resulting in a total 
response rate of 80% [8].
Population Characteristics
The mean age of the study population was 47 (SD ±15) 
years (Table 1). This cohort has been described and the 
data presented in Table 1 has been published previously 
[8].
All patients had a confirmed MEN1 mutation, or one 
or more MEN1-related manifestations and a first-degree 
relative with MEN1. Eighty-three percent of patients re-
ported ever having had a pPHT. More than half of the 
patients reported ever having had a pNET (55%) and 38% 
of patients had a self-reported pituitary tumor.
Health-Related Quality of Life
HRQOL scores in MEN1 patients, adjusted for age and 
gender, were significantly lower for the majority of sub-
scales of the Health Related Quality of Life SF-36 in com-
parison with the general Dutch population (Fig. 1). The 
subscales general health perceptions and vitality were 0.5 
SD lower, which can be considered as a clinically relevant 
difference. The only scale that was comparable with the 
general population was the physical functioning scale.
Self-Reported Manifestations versus Manifestations 
according to the Medical Records
Only one (3%) of 31 patients who, according to the 
medical records, did not have a pHPT reported having 
a pHPT. A total of 7 (4%) of 192 patients with pHPT 





























Years since MEN1 diagnosis
<5 years 27 (12%)
≥5 years 190 (84%)
The data presented here have been published previously [8].
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according to their medical record, were unaware of hav-
ing a pHPT. Twenty-three (16%) of the total of 140 pa-
tients who according to the medical record had a pNET 
reported that they did not have and never had a pNET. 
The median size of the pNET of these patients was 8.5 
mm (IQR 4–13 9) compared to 13 mm (IQR 9–17) in 
patients who accurately reported having a pNET. One 
of those patients even had pancreatic surgery for a 
pNET.
Six (5%) of the 122 patients who according to the med-
ical records did not have and never had a pNET, reported 
having a pNET. Twenty-nine (29%) of 101 patients who 
ever had a pituitary tumor according to the medical rec-
ords, reported that they did not have and never had a pi-
tuitary tumor. The median size of the pituitary tumors in 
this group was 5 mm (IQR 4–6) compared to 5 mm (IQR 
3–7) in patients who accurately reported having a pitu-








































































Fig. 1. Mean SF-36 scores of MEN1 pa-






















Have a PIT, but say they don’t
PIT according to patients
Fig. 2. HRQOL scores of patients with a pi-
tuitary tumor (PIT) in comparison with 
patients who do not think they have a PIT, 
but they do according to the medical data. 
Physical role (p = 0.01), emotional func-
tioning (p = 0.02), and mental health (p = 
0.02).
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sphenoidal resection for a pituitary tumor. Four (5%) of 
85 patients who never had a pituitary tumor thought they 
did have a pituitary tumor.
Patients who reported not having a pNET, but had a 
pNET according to the medical records, had slightly better 
HRQOL scores in comparison with patients who reported 
ever having had a pNET. This difference was significant 
for the emotional functioning score, with mean scores of 
85.9 and 65.4, respectively (CI –35.4 to –5.6; p = 0.03).
Patients who ever had a pituitary tumor diagnosis as 
reported in their medical records, but reported not hav-
ing a pituitary tumor, had better HRQOL scores than pa-
tients who reported having or having had a pituitary tu-
mor (Fig. 2). This difference was significant for the phys-
ical role (p = 0.01), emotional functioning (p = 0.02), and 
mental health (p = 0.02) subscale.
Univariate Analysis
In univariate analyses, age, years since MEN1 diagno-
sis, education level, pituitary tumor, index cases, and em-
ployment were significantly related to 2 or more subscales 
of the Health Related Quality of Life SF-36 (online suppl. 
data; see www.karger.com/doi/10.1159/000508374).
Multivariable Analysis
The multivariable analyses included age, the presence 
of a pNET, pHPT, pituitary tumor, years of diagnosis, ed-
ucation level, index case, employment (yes/no), and pres-
ymptomatic diagnosis (yes/no). The employment status, 
being an index case, and a pituitary tumor diagnosis were 
associated with HRQOL. Employment was the only pre-
dictor that was significantly related to all subscales, except 
for the emotional functioning scale (online suppl. data).
Employment Status
A subgroup analysis of patients before the retirement 
age was conducted since employment appeared to be 
such a crucial factor for HRQOL. Therefore, the group 
was divided according to employment status: employed 
(n = 154) and unemployed (n = 39; Table 2).
Age at completion of the questionnaire and education 
level were significantly different between the employed 
and unemployed group. The mean age of patients in the 
employed group was almost 10 years younger than the 
unemployed group; 42 and 51 years, respectively (p = 
0.01). Patients with a college or university degree (n = 61) 
had the highest percentage of employment (95%, n = 58) 
in comparison with patients with only primary education 
(n = 2, who were unemployed) or secondary education 
(n = 126, of whom 95 are employed; 75%; p = 0.01). Odds 
ratios and 95% CI of univariate and multivariable analy-
ses of active versus inactive employment status are pre-
sented in Table 2.
The multivariable analysis of patients below 65 years 
of age with the same variables as reported earlier showed 
the same outcomes, concluding that employment re-
mained a crucial predictor for HRQOL in patients with 
MEN1 (Table 2).




status (n = 39)
Active employment
status (n = 154)
Univariate analysis Multivariable analysis
OR 95% CI p value OR 95% CI p value
Age, years (range) 46 (19–64) 52 (19–64) 44 (20–64) 0.2 0.1–0.5 <0.01 0.9 0.9–0.99 0.02
Male 73 11 (15%) 62 (85%) 0.6 0.3–1.3 0.2
Female 120 28 (23%) 92 (77%)















pNET according to patients 105 24 (23%) 81 (77%) 0.7 0.3–1.4 0.3
PIT according to patients 77 18 (23%) 59 (77%) 0.7 0.4–1.5 0.4
pHPT according to patients 157 37 (24%) 120 (76%) 0.2 0.04–0.8 0.03 5.2 0.6–46.5 0.14
Years of diagnosis (range) 12 (0–46) 13 (4–46) 12 (0–32) 1.0 0.91–0.99 0.03 1.0 0.9–1.0 0.3
Presymptomatic 86 9 (10%) 77 (90%) 3.5 1.5–7.8 0.003 0.7 0.2–2.4 0.6
Index case 47 16 (34%) 31 (66%) 0.4 0.2–0.8 0.01 2.4 0.8–7.0 0.1
pNET, pancreatic neuroendocrine tumor; PIT, pituitary tumor; pHPT, primary hyperparathyroidism.
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Discussion
In this large nationwide study including a representa-
tive sample of MEN1 patients, QOL was significantly and 
clinically relevantly impaired in comparison with the 
general Dutch population. A worse HRQOL in MEN1 pa-
tients was suggested in previous studies with either se-
lected or small MEN1 populations [9, 10].
The present population revealed no difference in phys-
ical functioning in comparison with the general popula-
tion. However, reduced physical functioning compared 
with chronic conditions and the general population was 
found in a cohort part of the American MEN support 
group [17]. The discrepancy might be explained by a se-
lection of patients that experience (physical) impairment 
caused by the disease and therefore might have sought 
support in this group. Recruiting patients via support 
groups might result in a selection of patients and there-
fore result in different findings in comparison with a pop-
ulation-based study.
On the contrary, for other endocrine cancer syn-
dromes such as VHL and MEN2, HRQOL was compa-
rable with the general population. This is striking, be-
cause both syndromes have considerable morbidity [18, 
19].
An in-depth analysis revealed that the most consistent 
predictor for HRQOL was employment status, followed 
by the presence of a pituitary tumor. Employment was a 
robust predictor for HRQOL across all HRQOL sub-
scales. Employment has proven to be beneficial for health 
in general [20]; therefore, not being able to work can have 
a significant effect on the HRQOL. The percentage of un-
employment was 20% in this population. Unemployment 
in the Netherlands was approximately 5.5% during the 
time of this study, revealing a high percentage of unem-
ployment in MEN1 patients.
An online survey in 153 MEN1 patients who are part 
of the American MEN support group revealed that this 
group experienced significant financial burden and un-
employment, which were both correlated to worse 
HRQOL [17]. A similar effect of employment on HRQOL 
is observed in different malignancies [21]. In addition, in 
a MEN2 cohort, a higher physical functioning score was 
observed in actively working patients than in inactive 
subjects [19].
Both, losing a job because of health issues and being a 
long-term cancer survivor are risk factors for lower 
HRQOL [22]. Cancer survivors who continue to work 
have a better health and HRQOL than patients who are 
not able to work [23]. Since cancer survivorship is associ-
ated with unemployment, this group of patients is at risk 
of not returning to work [24]. In our study, an older age 
and lower levels of education were associated with unem-
ployment. This is in line with previous studies assessing 
predictors of unemployment of cancer survivors [25]. 
QOL and return to work seem to benefit from rehabilita-
tion programs [26]. Multidisciplinary interventions that 
combine vocational counselling, patient education/coun-
selling, and physical exercises showed higher return to 
work rates than care as usual [24]. Intervention studies 
assessing a similar rehabilitation program in MEN1 pa-
tients would be helpful to gain more insight in the value 
of these programs and to develop a MEN1-specific mul-
tidisciplinary reactivation program.
Remarkably, in a substantial proportion of patients, 
there was a discrepancy between the self-reporting of pa-
tients of having a pNET or pituitary tumor and the dis-
ease status as reported in their medical records. In 16 and 
29% of patients who reported not having a pNET or pitu-
itary tumor, the medical records showed the presence of 
these manifestations. Patients could not have been in-
formed properly or could have forgotten their own dis-
ease status or misunderstood the questions. Interestingly, 
patients who were not aware of having a pNET or a pitu-
itary tumor had a better HRQOL compared to patients 
who were aware of their disease status. When compared 
with patients having a pNET, the differences of HRQOL 
between those who were aware compared to those un-
aware, was worse in patients having a pituitary tumor. 
This suggests that in particular the knowledge of patients 
that they have a pituitary tumor played a significant role 
in the HRQOL.
This finding also suggests that cognitive avoidance can 
be present. This is a coping mechanism that functions as 
a psychological defense and has been described in a MEN2 
population, primarily occurring in cured patients [19]. 
Most MEN1-related tumors remain stable and asymp-
tomatic, and require no treatment. In these cases, the ma-
jor burden is the knowledge about the disease status with-
out a direct clinical consequence. This requires specific 
coping strategies in dealing with lifelong disease burden 
with an insecure outcome necessitating specific attention.
Limitations
The cross-sectional design of the study does not allow 
assessing the HRQOL in the course of the disease. A lon-
gitudinal study would give insight into the variability of 
HRQOL in the course of MEN1-related therapies and 
surveillance. The heterogeneity of MEN1, with its vari-
able disease prevalence, various treatment options, and 
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strict follow-up regimen sets the ideal basis for a longitu-
dinal HRQOL study. Long-term distress is more likely to 
occur in this population than short-term distress. This 
was also seen in a MEN2 cohort with relatively more de-
pression and anxiety [19].
Strengths
A major strength is the high response rate of 80% of this 
study contributing to the validity and generalizability of 
the study. Another major strength is the availability of the 
DMSG longitudinal MEN1 database comprising an ex-
tensive clinical dataset. Data filled out by the respondents 
could therefore be cross-referenced from this database.
Clinical Implications
Because of the reduced HRQOL, special attention of 
care providers for this aspect should be routine in the reg-
ular care for patients with MEN1. Integrating structured 
HRQOL assessments to the surveillance program will pro-
vide more insight into the perceived burden of patients 
with MEN1 and the HRQOL in the course of the disease. 
This will ultimately contribute to improving the quality of 
this aspect of MEN1 patient care. Management of MEN1 
patients in a multidisciplinary team, preferably including 
a psychologist, can be of benefit for this population.
Patient counselling on the natural course of the disease 
and possible treatment options are imperative to provide 
insight into the disease. Tumors have malignant potential, 
but genetic testing to pursue early diagnosis and subse-
quent surveillance has decreased morbidity and mortality 
[27]. This information might assure patients to adhere to 
the current screening protocols and be assured that an ear-
ly diagnosis will lead to an improved overall outcome. To 
prevent the discordance between patients’ self-reported 
and actual disease status, physicians should pay special at-
tention to the patients’ understanding of the disease and 
review whether their disease insight is accurate.
Physicians should be especially aware of the impact of 
the relationship between unemployment and HRQOL. 
Unemployed patients should be considered as high-risk 
patients for worse HRQOL. Multidimensional rehabilita-
tion programs might be helpful in returning to work and 
hereby improving HRQOL.
Conclusions
In this, up to now largest unselected MEN1 cohort, 
patients with MEN1 have an impaired QOL in compari-
son with the general Dutch population. Unemployment 
and having a pituitary tumor are consistent predictors for 
a worse QOL. Awareness of patients’ actual disease status 
influences their QOL. Lack of awareness results in better 
QOL. For daily practice, physicians should be aware of 
their patients’ impaired QOL and the impact of unem-
ployment on the QOL. A multidisciplinary approach in 
this population is warranted and will benefit the care for 
patients with MEN1.
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